OBJECTIVE: To identify predictors of community-onset extended-spectrum β-lactamase (ESBL)-producing Escherichia coli infection. DESIGN: Prospective case-control study. SETTING: Acute care hospitals and ambulatory clinics in the Chicago, Illinois, region. PATIENTS: Adults with E. coli clinical isolates cultured in ambulatory settings or within 48 hours of hospital admission. METHODS: Cases were patients with ESBL-producing E. coli clinical isolates cultured in ambulatory settings or within 48 hours of admission, and controls were patients with non-ESBL-producing E. coli isolates, matched to cases by specimen, location, and date. Clinical variables were ascertained through interviews and medical record review. Molecular methods were used to identify ESBL types, sequence type ST131, and aac(6')-Ib-cr. RESULTS: We enrolled 94 cases and 158 controls. Multivariate risk factors for ESBL-producing E. coli infection included travel to India in the past year (odds ratio [OR], 14.40 [95% confidence interval (CI), 2.92-70.95]), ciprofloxacin use (OR, 3.92 [95% CI, 1.90-8.1]), and age (OR, 1.04 [95% CI, 1.02-1.06]). Case isolates exhibited high prevalence of CTX-M-15 (78%), ST131 (50%), and aac(6')-Ib-cr (66% of isolates with CTX-M-15). CONCLUSIONS: Providers should be aware of the increased risk of ESBL-producing E. coli infection among returned travelers, especially those from India.
OBJECTIVE: To identify predictors of community-onset extended-spectrum β-lactamase (ESBL)-producing Escherichia coliinfection. DESIGN: Prospective case-control study. SETTING: Acute care hospitals and ambulatory clinics in the Chicago, Illinois, region. PATIENTS: Adults with E. coli clinical isolates cultured in ambulatory settings or within 48 hours of hospital admission. METHODS: Cases were patients with ESBL-producing E. coli clinical isolates cultured in ambulatory settings or within 48 hours of admission, and controls were patients with non-ESBL-producing E. coli isolates, matched to cases by specimen, location, and date. Clinical variables were ascertained through interviews and medical record review. Molecular methods were used to identify ESBL types, sequence type ST131, and aac(6')-Ib-cr. RESULTS: We enrolled 94 cases and 158 controls. Multivariate risk factors for ESBL-producing E. coli infection included travel to India in the past year (odds ratio [OR], 14.40 [95% confidence interval (CI), 2.92-70.95]), ciprofloxacin use (OR, 3.92 [95% CI, 1.90-8.1]), and age (OR, 1.04 [95% CI, 1.02-1.06]). Case isolates exhibited high prevalence of CTX-M-15 (78%), ST131 (50%), and aac(6')-Ib-cr (66% of isolates with CTX-M-15). CONCLUSIONS: Providers should be aware of the increased risk of ESBL-producing E. coli infection among returned travelers, especially those from India.
Authors: Cheol-In Kang; Yu Mi Wi; Mi Young Lee; Kwan Soo Ko; Doo Ryeon Chung; Kyong Ran Peck; Nam Yong Lee; Jae-Hoon Song Journal: J Clin Microbiol Date: 2011-12-07 Impact factor: 5.948
Authors: Hiran Dhanji; Rajesh Patel; Robert Wall; Michel Doumith; Bharat Patel; Russell Hope; David M Livermore; Neil Woodford Journal: J Antimicrob Chemother Date: 2011-02-24 Impact factor: 5.790
Authors: Yohei Doi; Yoon Soo Park; Jesabel I Rivera; Jennifer M Adams-Haduch; Ameet Hingwe; Emilia M Sordillo; James S Lewis; Wanita J Howard; Laura E Johnson; Bruce Polsky; James H Jorgensen; Sandra S Richter; Kathleen A Shutt; David L Paterson Journal: Clin Infect Dis Date: 2012-11-13 Impact factor: 9.079
Authors: Muhanad Mohamed; Connie Clabots; Stephen B Porter; Tricia Bender; Paul Thuras; James R Johnson Journal: J Infect Dis Date: 2020-04-27 Impact factor: 5.226
Authors: Benjamin A Rogers; Paul R Ingram; Naomi Runnegar; Matthew C Pitman; Joshua T Freeman; Eugene Athan; Sally M Havers; Hanna E Sidjabat; Mark Jones; Earleen Gunning; Mary De Almeida; Kaylene Styles; David L Paterson Journal: Antimicrob Agents Chemother Date: 2014-01-27 Impact factor: 5.191
Authors: Latania K Logan; Liqing Zhang; Stefan J Green; Samuel Dorevitch; Gustavo A Arango-Argoty; Kendrick Reme; Emily Garner; Jared Aldstadt; Yvette J Johnson-Walker; Mary K Hayden; Robert A Weinstein; Amy Pruden Journal: Antimicrob Agents Chemother Date: 2020-03-24 Impact factor: 5.191